Prevalence and Mutation Rate of Lipa Gene in LIPIGEN Subjects With Clinical Diagnosis of FH

Status: Unknown
Location: See all (4) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

Familial Hypercholesterolemia (FH) is a monogenic autosomal dominant disease also known as Autosomal Dominant Hypercholesterolemia - ADH) that leads to dramatically increased levels of Low Density Lipoprotein (LDL) and total cholesterol associated to tendon xanthomas, xanthelasma, corneal arcus, premature atherosclerosis and to an increased risk of coronary artery disease (CAD) and myocardial infarction. FH is mainly caused by mutations in genes encoding for proteins affecting hepatic LDL cholesterol uptake including the LDL receptor (LDLR) gene or the gene encoding the only apolipoprotein of LDL, the apolipoprotein B (APOB), or the gene encoding a protease regulating LDLR levels on the cell membrane Lysosomal Acid Lipase A (LIPA) gene encode for Lysosomal acid lipase (LAL) enzyme responsible for hydrolyzing cholesterol esters and triglycerides that are delivered to lysosomes. Mutations in LIPA that completely inactivate LAL are the molecular cause of Wolman disease, a rapidly lethal disease of infancy while mutations in LIPA that result in residual enzymatic activity of LAL are responsible of a disorder characterized by a less severe phenotype known as cholesterol ester storage disease (CESD). Patients with CESD usually show a phenotype characterized by hepatic disease and mixed hyperlipidemia with elevated levels of LDL-C and triglycerides (TG) and decreased HDL-C levels. A broader phenotypic presentation for loss of function mutations in LIPA suggests that LIPA mutations may be considered in patients with apparently monogenic FH in whom mutations in the known candidate genes are not detectable. The project is aimed to evaluate the prevalence and the mutation rate of LIPA gene in subjects with a clinical diagnosis of FH and already genetically characterized in whom pathogenic mutations in the known candidate genes have not been identified. The analysis will be performed in about 250 FH pediatric subjects and putative causal mutations will be also tested for co-segregation in available families in affected and unaffected members.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 18
Healthy Volunteers: f
View:

• Pediatric subjects (\<18 years old) with a clinical diagnosis of FH and without identified pathogenic mutations in the known candidate genes.

Locations
Other Locations
Italy
CENTRO PER LO STUDIO DELL'ATEROSCLEROSI - Ospedale Bassini
RECRUITING
Cinisello Balsamo
Laboratorio di biochimica delle lipoproteine - DIPARTIMENTO DI SCIENZE BIOMEDICHE
RECRUITING
Modena
Centro Di Riferimento Regionale Per La Prevenzione, Diagnosi E Cura Delle Malattie Rare Del Metabolismo
RECRUITING
Palermo
Centro Per L'Arteriosclerosi Dipartimento Di Medicina Interna E Specialità Mediche
RECRUITING
Roma
Contact Information
Primary
Alberico L Catapano
alberico.catapano@unimi.it
Backup
Alessia Tincani
catapano.centroatero@gmail.com
+39026173276
Time Frame
Start Date: 2017-09-01
Completion Date: 2023-07-01
Participants
Target number of participants: 1000
Treatments
FH pediatric patients
1000 clinically diagnosed FH pediatric patients (age \<18 years) included in the LIPIGEN (Lipid TransPort Disorders italian Genetic Network) database
Sponsors
Leads: Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.